Renexxion
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact

News

Press

July 17, 2018
Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China
Download.pdf
Nov. 17, 2016
Bioworld:  ​Renexxion advances former Aryx GI drug under new FDA guidance
Nov. 16, 2016
Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
Download .pdf
Privacy Policy & Terms of Use 
​Copyright Renexxion 2016. All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Latest Regulatory Developments
  • Knowledge Center
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
    • Gastroparesis
    • Other Therapeutic Indications
  • News
    • Press >
      • Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
      • Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
  • Contact